title: rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine.
abstract: Protein bioconjugates can be synthesized by using chemical reactions, enzymatic reactions or genetic engineering technologies. Naturally occurred protein fusion event is used on purpose in the development of better biopharmaceuticals by applying genetic engineering methodologies. This review will mainly focus on the types of fusion proteins produced with the use of recombinant DNA technology, by combining genes or parts of genes from the same or different organisms, in order to be used in pharmaceutical applications for several purposes. Main concerns for the development of better biopharmaceuticals include quality, efficacy, safety, immunogenicity and toxicity issues. Extending half-life of the drug to increase patient compliance, targeting the drugs to reduce toxicity, improving the manufacturing environment to reduce the costs and revealing protein interaction technologies to find novel and superior drugs are the main aims of fusion protein production. Here, related tags and examples of fusion methods for different purposes will be explained precisely.
authors.affiliation: Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
authors.forename: Ayse Goksu
authors.initials: AG
authors.lastname: Kaya-Ozsan
authors.affiliation: Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Hacettepe University, P.O. Box: 06100, Ankara, Turkey.
authors.forename: Ayse Filiz
authors.initials: AF
authors.lastname: Oner
mesh_terms: D000818:Animals; D004274:DNA, Recombinant / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use*
chemical_list: D004274:DNA, Recombinant; D004364:Pharmaceutical Preparations; D011993:Recombinant Fusion Proteins
keywords: Antibodies; Bioconjugates; Engineered protein; Fc fusion; Fusion proteins; Half-life extension; Targeting